Monitor European Commission decision expected within 2-3 months; if adopted, watch for national immunization program updates in countries with existing infant MenB programs, as adolescent booster recommendations could drive volume growth for Bexsero.
Drug in focus
GSK drug pipeline →Bexsero
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed (US since 2015, EU since 2013). The booster label expansion for ages 10+ is under EMA review with a positive CHMP opinion; European Commission decision expected within 1-2 months.
- Next catalyst
- None dated
What to watchThe CHMP recommended Bexsero's label expansion for a single booster dose on November 13, 2026. The European Commission typically follows CHMP recommendations within 1-2 months, which would be the next catalyst. If approved, this expands the addressable adolescent/young adult booster market in Europe. Separately, Bexsero is being studied for cross-protection against gonorrhea, a potential long-term value driver, but no pivotal readout is scheduled.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $50.45entry
- T+1 · 17h ago −0.08%α +1.83% · $50.41
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced that the EMA's CHMP has issued a positive opinion recommending a label update for Bexsero (4CMenB) to include a single booster dose for individuals aged 10+ previously vaccinated at least two years earlier. The recommendation is based on Phase IIIb data showing immune memory established in infancy can be boosted up to 19 years later. This is a regulatory milestone that could expand Bexsero's addressable adolescent booster market in Europe if adopted by the European Commission.
Key Facts
- CHMP recommended updating Bexsero label to include a single booster dose for individuals aged 10 years and older previously vaccinated at least two years earlier
- Recommendation based on Phase IIIb study Men-B-096 (312 participants) which met its primary endpoint
- Bexsero is registered in 61 countries, included in 15 national/regional infant immunization programs and 3 adolescent programs in Europe
- Around 140 million doses of Bexsero distributed globally since 2015
- Serogroup B is the leading cause of invasive meningococcal disease in all age groups under 65 in Europe
Financial Impact
No financial figures stated in the filing; Bexsero is an established vaccine with existing market penetration; label expansion could incrementally boost sales but magnitude is not quantified
Risk Factors
- CHMP opinion is non-binding; European Commission may not adopt the recommendation
- Adoption by national immunization programs is not guaranteed and may take time
- No financial impact or revenue guidance provided in the filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009743 |
| Document: 0001654954-26-009743-index-headers.html | 0001654954-26-009743 |
| Document: 0001654954-26-009743-index.html | 0001654954-26-009743 |
| Document: 0001654954-26-009743.txt | 0001654954-26-009743 |
| Earnings Context (Synthetic; results releases only) | 0001654954-26-009743 |
Track record
64 reports on GSK
9 of 18 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Viewing Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers